ABCL688 — IND submission
2026
We anticipate submission of an IND/CTA for ABCL688 in 2026.Source filing
ABCELLERA BIOLOGICS INC · Data as of 2026-09-08
2026
We anticipate submission of an IND/CTA for ABCL688 in 2026.Source filing
Q4 2026
● Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026.Source filing
2027
We anticipate submission of an IND/CTA for ABCL688 in 2027.Source filing